Taipei Medical University Institutional Repository:Item 987654321/61123
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 45069/58245 (77%)
造訪人次 : 2369193      線上人數 : 167
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/61123


    題名: 開發可以一步驟增殖並武裝T 細胞之雙功能抗體以進行腫瘤專一性治療
    Development of the bispecific antibody to one-step expand and arm T cells for selective tumor therapy
    作者: 蔡宜珊
    Tsai, Yi-Shan
    貢獻者: 臨床藥物基因體學暨蛋白質體學碩士學位學程
    莊國祥
    關鍵詞: anti-EGFR x anti-CD3;活體外分化和增生CD3+ T細胞;細胞毒殺
    anti-EGFR x anti-CD3;differentiated and expanded T cell ex vivo;cytotoxicity
    日期: 2016
    上傳時間: 2021-11-21 20:40:22 (UTC+8)
    摘要: T細胞治療為癌症之一種新興療法;然而,傳統T 細胞缺乏腫瘤專一性,為使其具有專一性則須花費過長時間培育或因利用基因轉殖技術隱藏基因突變潛在問題。為克服這些問題,我們希望開發一新型雙功能抗體,於活體外一步驟快速武裝T細胞成腫瘤專一性(arm-T),藉此提升臨床上癌症病患的腫瘤治療效果,並且更進一步利用雙功能抗體增生分化T 細胞,達到簡單且低免疫源性之治療。研究結果顯示我們成功利用基因工程建構新型雙功能抗體,anti-EGFR x anti-CD3 BsAb,並利用流式細胞儀確定其具有結合腫瘤和T細胞之雙邊功能,在活體外T細胞毒殺腫瘤實驗證實,arm-T細胞相較於傳統T細胞毒殺EGFR+大腸癌細胞之能力由3.8%提升至27%(E:T=5:1)及1.2%提升至45% (E:T=10:1)且在SCID小鼠腫瘤抑制實驗中arm-T細胞也大幅提升腫瘤抑制能力,更重要是成功利用含雙功能抗體之生長液於活體外分化增生人類之CD3+CD8+T細胞並同時間進行武裝動作,在活體外T細胞毒殺腫瘤實驗中證實,以此方式所增生之T 細胞其毒殺能力優於傳統OKT3培養法。本研究利用雙功能抗體於T細胞療法中快速達成高度腫瘤專一性且低免疫性之一種再現性佳的腫瘤治療模式。
    Adoptive cell transfer is personalized immunotherapy for human cancer. However, conventional T cell therapy lacks of tumor specificity or make it specificity by long-term ex vivo culture. Although CAR-T solve the problem, virus transfection is other worries in the future. Additionally, so far differentiated and expanded T cell by adding murine antibody, OKT3, it may enhance human anti-mouse antibody response. To overcome these problems, we develop the bispecific antibody to one-step expand and arm T cells for selective tumor therapy, then improve quality of life. In our study, we successfully have developed a novel bispecific antibody, anti-EGFRxanti-CD3 BsAb, proved bilateral function by flow cytometry. In vitro cytotoxicity test, the ability of arm-T is raise up to 27% from 3.8% at E/T ratio 5:1 and 45% from 1.2% at E/T ratio 10:1 .In vivo, arm-T also significantly suppress tumor growth in SCID mice. Finally, we successfully differentiate and expand PBMC to CD3+CD8+T cell by adding our anti-EGFR x anti-CD3 BsAb in culture medium, at the same time, arming CD3+T cell in one step. The cytotoxicity show higher efficiency than traditional expended way (by OKT3). In summary, our study provide a highly and rapidly tumor specificity and low toxicity way in adoptive T cell therapy.
    描述: 碩士
    指導教授:莊國祥
    資料類型: thesis
    顯示於類別:[臨床藥物基因體學暨蛋白質體學碩士學位學程] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML1090檢視/開啟


    在TMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋